Reports Q2 revenue $622.85M vs. $89.57M last year. As of June 30, 2025, Lipocine (LPCN) had $17.9M of unrestricted cash, cash equivalents and marketable investment securities compared to $21.6M at December 31, 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPCN:
- Buy Rating for Lipocine: LPCN 1154’s Promising Potential in Postpartum Depression Treatment
- Lipocine Hosts Virtual Event on LPCN 1154
- Lipocine Updates Corporate Presentation for Investors
- Positive Outlook on Lipocine: Promising Clinical Developments and Commercial Prospects Support Buy Rating
- Lipocine Begins Phase 3 Trial for LPCN 1154